Top & Current
Wed, September 4, 2024
[ Wed, Sep 04th 2024
] - WOPRAI
Tue, August 6, 2024
[ Tue, Aug 06th 2024
] - WOPRAI
Tue, June 25, 2024
[ Tue, Jun 25th 2024
] - WOPRAI
Thu, May 9, 2024
[ Thu, May 09th 2024
] - WOPRAI
Tue, May 7, 2024
[ Tue, May 07th 2024
] - WOPRAI
Wed, April 24, 2024
[ Wed, Apr 24th 2024
] - WOPRAI
Tue, March 26, 2024
Wed, January 31, 2024
Tue, December 12, 2023
[ Tue, Dec 12th 2023
] - WOPRAI
Tue, March 28, 2023
[ Tue, Mar 28th 2023
] - WOPRAI
Wed, January 25, 2023
[ Wed, Jan 25th 2023
] - WOPRAI
Tue, November 1, 2022
Wed, April 6, 2022
Thu, January 6, 2022
[ Thu, Jan 06th 2022
] - WOPRAI
Tue, April 13, 2021
Thu, February 18, 2021
[ Thu, Feb 18th 2021
] - WOPRAI
[ Thu, Feb 18th 2021
] - WOPRAI
Wed, November 13, 2019
[ Wed, Nov 13th 2019
] - WOPRAI
Tue, February 26, 2019
Mon, February 29, 2016
Tue, July 30, 2013
[ Tue, Jul 30th 2013
] - WOPRAI
Yaron Werber Maintained (ASND) at Strong Buy with Decreased Target to $157 on, Sep 4th, 2024
Yaron Werber of TD Cowen, Maintained "Ascendis Pharma A/S" (ASND) at Strong Buy with Decreased Target from $175 to $157 on, Sep 4th, 2024.
Yaron has made no other calls on ASND in the last 4 months.
There are 4 other peers that have a rating on ASND. Out of the 4 peers that are also analyzing ASND, 1 agrees with Yaron's Rating of Hold. Following is the relevant analyst calls for the last 4 months
- Vikram Purohit of "Morgan Stanley" Maintained at Hold with Increased Target to $140 on, Thursday, May 16th, 2024
These are the ratings of the 3 analyists that currently disagree with Yaron
- Kelly Shi of "Jefferies" Maintained at Strong Buy with Increased Target to $196 on, Tuesday, August 13th, 2024
- Paul Choi of "Goldman Sachs" Maintained at Strong Buy with Increased Target to $195 on, Tuesday, August 13th, 2024
- Alex Thompson of "Stifel" Initiated at Strong Buy and Held Target at $200 on, Friday, May 31st, 2024